Santos, ArnoldoMartínez-Milla, JuanPérez-Calvo, CésarIbáñez, Borja2023-04-112023-04-112022-01-04J Am Coll Cardiol. 2022 Jan 4;79(1):e13-e14http://hdl.handle.net/20.500.12105/15766engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19MetoprololAdministration, IntravenousAdrenergic beta-1 Receptor AntagonistsHumansSARS-CoV-2Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19.Attribution-NonCommercial-NoDerivatives 4.0 Internacional34991793791e1310.1016/j.jacc.2021.10.0301558-3597Journal of the American College of Cardiologyopen access